Huadong Medicine (000963.SZ) subsidiary's marketing authorization application for Cavilerone Tromethamine Tablets accepted

Zhitong Finance APP News, Huadong Medicine (000963.SZ) announced that on November 2, 2026, the company's wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. ("Zhongmei Huadong") received the Notice of Acceptance issued by the National Medical Products Administration (NMPA), and the marketing authorization application for the oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist carvilelon tromethamine tablets (development code: HDM1002 tablets) for long-term weight control in adults has been accepted.